NCT06393764 Cancer-related Venous Thromboembolic Disease - Cohort Study
| NCT ID | NCT06393764 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Thrombosis Embolism |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2035-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2025-10-30 with a primary completion date of 2035-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and more. * Patients with active cancer or requiring cancer treatment at the time of their VTE episode * Patients with documented VTE less than 2 years old * Patients affiliated to the social security system * Patient who has signed a written informed consent Exclusion Criteria: * Patient under 18 * Refusal to participate * Incapacity to consent to the study * Patient under guardianship * Incapacity to communicate (comprehension disorder) * Life expectancy of less than 6 months
Contact & Investigator
Françis Couturaud, Pr
PRINCIPAL INVESTIGATOR
CHU Brest
Frequently Asked Questions
Who can join the NCT06393764 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Thrombosis Embolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06393764 currently recruiting?
Yes, NCT06393764 is actively recruiting participants. Contact the research team at francis.couturaud@chu-brest.fr for enrollment information.
Where is the NCT06393764 trial being conducted?
This trial is being conducted at Brest, France.
Who is sponsoring the NCT06393764 clinical trial?
NCT06393764 is sponsored by University Hospital, Brest. The principal investigator is Françis Couturaud, Pr at CHU Brest. The trial plans to enroll 150 participants.